Clene Announces $7 Million Registered Direct Equity Offering

An update from Clene ( (CLNN) ) is now available.

On May 5, 2026, Clene Inc. priced a $7 million underwritten registered direct offering of 1,000,000 shares of common stock at $7.00 per share to a single investor, with Canaccord Genuity acting as sole bookrunner and Maxim Group and D. Boral Capital serving as financial advisers. The company expects net proceeds of about $6.4 million after fees, with the deal scheduled to close on or about May 6, 2026, subject to customary conditions, and key insiders agreeing to a 60-day lock-up restricting share sales and related transactions.

Clene plans to use the capital, together with existing cash, for general corporate purposes and to advance its lead candidate CNM-Au8, including preparation and filing of a new drug application, support for ongoing expanded access protocols and a future confirmatory Phase 3 trial, manufacturing expansion, and early-stage R&D. The financing underscores Clene’s effort to shore up its balance sheet and fund late-stage development and potential commercialization activities in neurodegenerative diseases, a critical step for stakeholders as the company moves closer to pivotal regulatory milestones for CNM-Au8.

The most recent analyst rating on (CLNN) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Spark’s Take on CLNN Stock

According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.

The score is held down primarily by very weak financial performance (large ongoing losses, sustained cash burn, and negative equity), which increases reliance on external funding. Technicals and recent regulatory-related corporate updates provide meaningful upside signals, but valuation remains constrained by unprofitability and no dividend support.

To see Spark’s full report on CLNN stock, click here.

More about Clene

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis. Its lead investigational therapy, CNM-Au8, is an oral suspension of gold nanocrystals designed to enhance cellular energy production for neuroprotection and remyelination, with the company based in Salt Lake City and R&D and manufacturing operations in Maryland.

Clene’s portfolio centers on CNM-Au8 as a first-in-class candidate targeting mitochondrial function and the NAD pathway while reducing oxidative stress in central nervous system cells. The company aims to advance this platform toward regulatory submission and potential commercialization in major neurodegenerative indications, positioning itself within a high-need segment of the biopharmaceutical market.

Average Trading Volume: 447,773

Technical Sentiment Signal: Buy

Current Market Cap: $95.29M

For detailed information about CLNN stock, go to TipRanks’ Stock Analysis page.